amgreat20200630

0001185185-21-000951.txt : 20210713 0001185185-21-000951.hdr.sgml : 20210713 20210712192728 ACCESSION NUMBER: 0001185185-21-000951 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20210713 DATE AS OF CHANGE: 20210712 FILER: COMPANY DATA: COMPANY CONFORMED NAME: America Great Health CENTRAL INDEX KEY: 0001098009 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980178621 STATE OF INCORPORATION: CA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27873 FILM NUMBER: 211086460 BUSINESS ADDRESS: STREET 1: 1609 W VALLEY BLVD UNIT 338A CITY: ALHAMBRA STATE: CA ZIP: 91803 BUSINESS PHONE: (626) 576-1299 MAIL ADDRESS: STREET 1: 1609 W VALLEY BLVD UNIT 338A CITY: ALHAMBRA STATE: CA ZIP: 91803 FORMER COMPANY: FORMER CONFORMED NAME: CROWN MARKETING DATE OF NAME CHANGE: 20111006 FORMER COMPANY: FORMER CONFORMED NAME: SPACE LAUNCHES FINANCING INC DATE OF NAME CHANGE: 19991028 10-K 1 amgreat20200630_10k.htm FORM 10-K amgreat20200630_10k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended June 30, 2020

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-27873

America Great Health

(Exact name of registrant as specified in its charter)

Wyoming

(State or other jurisdiction of incorporation or organization)

98-0178621

(I.R.S. Employer Identification No.)

1609 W Valley Blvd Unit 338A, Alhambra, CA

(Address of principal executive offices)

91803

(Zip Code)

Registrant’s telephone number, including area code: (626) 576-1299

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common Stock, no par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Yes ☐ No ☒

Indicate by check mark whether the registrant is large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” accelerated filer” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer ☐		Accelerated filer ☐

Non-accelerated filer ☐		Smaller Reporting Company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. The number of shares outstanding of the registrant’s common stock as of July 12, 2021 was 21,070,866,399.

FORM 10-K

For the Year Ended June 30, 2020

TABLE OF CONTENTS

		Page
PART I
Item 1.	Business	5
Item 1A.	Risk Factors	7
Item 1B.	Unresolved Staff Comments	7
Item 2.	Properties	7
Item 3.	Legal Proceedings	7
Item 4.	Mine Safety Disclosures	7
PART II
Item 5.	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	8
Item 6.	Selected Financial Data	9
Item 7.	Management's Discussion and Analysis of Financial Condition and Results of Operations	10
Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	13
Item 8.	Financial Statements and Supplementary Data	13
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	13
Item 9A.	Controls and Procedures	13
Item 9B.	Other Information	14
PART III
Item 10.	Directors, Executive Officers and Corporate Governance	15
Item 11.	Executive Compensation	15
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	16
Item 13.	Certain Relationships and Related Transactions, and Director Independence	16
Item 14.	Principal Accounting Fees and Services	17
PART IV
Item 15.	Exhibits, Financial Statement Schedules	18
Signatures		20

In this annual report the words "we," "us," "our," and the "Company" refer to Crown Marketing and subsidiaries.

FORWARD LOOKING STATEMENTS

When used in this report, the words “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding events, conditions, and financial trends that may affect the Company’s future plans of operations, business strategy, operating results, and financial position. Persons reviewing this report are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and that actual results may differ materially from those included within the forward-looking statements as a result of various factors.

Statements made in this Form 10-K that are not historical or current facts are "forward-looking statements" made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent our best judgment as to what may occur in the future. These forward-looking statements include our plans and objectives for our future growth, including plans and objectives related to the consummation of acquisitions and future private and public issuances of our equity and debt securities. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this Form 10-K will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, you should not regard the inclusion of such information as our representation or the representation of any other person that we will achieve our objectives and plans. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

Table of Contents

PART I

ITEM 1. BUSINESS

Historical Development

America Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.

On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.

On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.

On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China.

Our Business

Prior to the change of controlling ownership of the common stock, the Company sold consumer products. It acquired electronic products from manufactures and then sold them directly to consumers so as to be more competitive in price. As of December 31, 2016, the Company ceased operations in this line of business.

The Company under the new management will focus its business in the health related industry. The Company’s Chairman and president, Mike Wang, is the owner of several health related businesses below with which The Company is evaluating the possibilities of forming several joint ventures. The Company might effectuate the joint ventures using stock.

Health & Beauty Group Inc (“H&BG”). It is a California company in the business of research and development (“R&D”) and sale of vitamins and nutritional supplements. It owns more than 20 formulas and engages contract manufacturers to make these products. H&BG has built up sales records both in the US as well as in China. On January 4, 2018, the Company entered into a Stock Purchase Agreement with H&BG (the “Seller”) to purchase 51% of common shares of the Seller, for $765,000, which consisted of 63,750,000 outstanding shares of the Company’s common stock at $0.012 per share. On April 5, 2018, the Company entered into a Rescission Agreement (the “Rescission Agreement”) with the seller to rescind the transactions set forth in the Stock Purchase Agreement prior to the transaction closing.

Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare, LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also provide Total Solution Services related with the use of the Equipment.

Sales Agreement between Mike Wang and Dr. William Fang for the marketing and sales of Dr. Fang’s early detection system of Cardio Vascular diseases. The device provides unique 3D imaging for the Cardio Vascular conditions for patients and has already won approval of US Food and Drug Administration (“FDA”). It has very positive significance in helping preventing heart attacks, which are the number one killer in the US as well as in the world.

On March 5, 2018, America Great Health, a California Corporation (“AAGH CA”), a wholly owned subsidiary of the Company, entered into a Sino-foreign Co-operative Joint Venture Contract (the “JV Agreement”) with Guangzhou Bona Biotechnology Co., Ltd. (“Bona”) to establish a JV, Pomeikang Biotechnology (Guangzhou) Co., Ltd. (“Pomeikang”), to promote and develop sales channels for health and cosmetics related products supplied by AAGH CA in the mainland of the People’s Republic of China, the Hong Kong Special Administration Region and the Macau Special Administration Region (together, the “China Market”).

Table of Contents

Pursuant to the JV Agreement, AAGH CA and Bona own 49% and 51% of Pomeikang, respectively, and AAGH California has the veto right to stop the majority shareholder’s decision. AAGH CA will contribute the initial products in equivalent of cash amount of RMB 2.45 million ($380,000) to Pomeikang and Bona will contribute any required operating capital, experienced sales team, promotional effort, and customer services to ensure normal day to day operation of Pomeikang. Bona will also be responsible for acquiring any required government permits, sales permits, and business licenses for Pomeikang.

At December 31, 2018, the Company decided to no longer participate in Pomeikang’s operations. On April 1, 2019, AAGH California transferred its 49% ownership to Bona for $1.

On May 21, 2018, the Company, entered into an Exclusive Oversea Distribution Agreement (the “Agreement”) with Foshan Wanshunbao Technology Co., Ltd. (“Wanshunbao”), a mainland China based company. According to the Agreement, Wanshunbao wishes to promote and develop oversea sales channels for its unique “Mysteries Fruit” tea and related products worldwide. The Company is appointed as Wanshunbao’s exclusive distributor to market and sell the “Mysteries Fruit” herbal tea and related products in geographic areas covers all over the world except mainland China.

In the past 20 years, Wangshunbao has dedicated to improve its R&D, and production of the unique “Mysteries Fruit” and related supplemental products, currently, Wangshunbao has developed a leading role in this industry, and is in the process of expanding its business model worldwide to a 10 billion RMB ($1,500,000,000) industry chain. To achieve that goal, Wangshunbao’s management team had been actively seeking a qualified international distributor and business partner to execute its expansion plan.

The Company’s management team was invited to Foshan, China in early May, 2018 to visit Wangshunbao and its production facilities, upon extensive discussion and negotiation, the Company was granted with exclusive distribution rights worldwide for “Mysteries Fruit” tea and related products. The Company believes by introducing “Mysteries Fruit” products to oversee consumers would have a huge beneficial effect; and the management is confident about this business opportunity, as the Company’s core team members all have been in health and supplemental related industry for over 20 years, and has substantial nutrient products sales experiences and marketing channels. The Company is currently conducting preliminary sales campaigns for “Mysteries Fruit” products.

The company and Blue Sea International Holdings Co., Ltd. signed a letter of intent on August 28, 2018. According to the letter of intent, Blue Sea International Holdings Co., Ltd. Intends to invest $50 million for the Company's marketing, product development, and merger and acquisition activities. The two parties also signed a marketing contract for 10,000 cardio vascular device after the Company obtains the necessary permit in China.

HuaHengJian (Beijing) Biotechnology Co., Ltd., Zhengzhou RuiBoSi Medical Devices Co., Ltd. and other companies have agreed to sell or lease more than 10,000 cardio vascular device in China after the Company obtains the necessary permit in China.

The company is negotiating an acquisition intention with Hongkong Pure Aesthetics Biotechnology Limited, which holds several patents in stem cell. The patents are valued at nearly $59 million.

The Company is discussing the possibility of establishing a joint venture in California with an individual who has nearly ten years experiences in health products market.

The Company is also planning to make additional acquisitions. Mike Wang has approached several health related companies in China and met the management of potential acquisition targets. Rapid economic advances in China in the last 30 years have greatly improved the living standards in China. This in turn brings demand in healthcare products and services. The Company feels strongly that despite the challenges of cross border business, it might be able to acquire some good growth companies and bring good values to our stockholders.

As inherent with any new business development, there are risks involved in such endeavors. For all the healthcare related businesses afore-mentioned, the Company is evaluating what kind of risks we are facing. The Company notices that vitamin and nutrition supplement business is a highly competitive market and faces multiple regulatory monitoring. The compliance challenge is constant. Regarding proton treatment sales, the device is very expensive and for such large ticket item, the procurement process can be long and arduous. The sale of cardio vascular device also has its challenges. The device is not well known and the acceptance of the use requires major efforts in educating not only the medical professionals but also consumers. This would demand financial as well as other resources. Although the Company is making some progress in the Merger and Acquisition efforts, any potential results, if any, are still not certain.

Table of Contents

Employees and Outside Services

The company only has one executive and financial officer who devotes full time to the affairs of the Company. Remaining administrative (non-policy making) officers and consultants and technical personnel such as marketing specialists are being compensated as independent contractors. We pay these persons on a contract basis as required.

ITEM 1A. RISK FACTORS

This item is inapplicable because we are a “smaller reporting company” as defined in Exchange Act Rule 12b-2.

ITEM 1B. UNRESOLVED STAFF COMMENTS

This item is inapplicable because we are a “smaller reporting company” as defined in Exchange Act Rule 12b-2.

ITEM 2. PROPERTIES

The Company currently is using a premise for free, the premise is leased by a company owned by its current majority shareholder.

ITEM 3. LEGAL PROCEEDINGS

No legal proceedings are threatened or pending against us or any of our officers or directors. Further, none of our officers, directors or affiliates are parties against us or have any material interests in actions that are adverse to the Company’s interests.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

Table of Contents

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common stock is currently listed on the OTC Bulletin Board under the symbol “AAGH”. There has been limited trading of the common stock from December 2, 2013 (Inception) through June 30, 2020. The last sale price of our common stock on May 21, 2021 was $0.1679 per share.

The following table sets forth the high and low transaction price for each quarter within the fiscal years ended June 30, 2020 and 2019, as provided by the Nasdaq Stock Markets, Inc. The information reflects prices between dealers, and does not include retail markup, markdown, or commissions, and may not represent actual transactions.

Fiscal Year Ended		Bid Prices
June 30,	Period	High		Low

2020	First Quarter	$	0.0195	$	0.0060
	Second Quarter	$	0.0180	$	0.0051
	Third Quarter	$	0.0150	$	0.0048
	Fourth Quarter	$	0.0120	$	0.0050

2019	First Quarter	$	0.0150	$	0.0090
	Second Quarter	$	0.0230	$	0.0090
	Third Quarter	$	0.0230	$	0.0098
	Fourth Quarter	$	0.0200	$	0.0090

Our shares are subject to Section 15(g) and Rule 15g-9 of the Securities and Exchange Act, commonly referred to as the “penny stock” rule. The rule defines penny stock to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions. The rule provides that any equity security is considered to be a penny stock unless that security is:

- registered and traded on a national securities exchange meeting specified criteria set by the SEC;

- issued by a registered investment company;

- excluded from the definition on the basis of price (at least $5.00 per share) or the issuer’s net tangible assets.

Trading in the penny stocks is subject to additional sales practice requirements on broker-dealers who sell penny stocks to persons other than established customers and accredited investors. Accredited investors, in general, include certain institutional investors and individuals with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse.

For transactions covered by these rules, broker-dealers must make a special suitability determination for the purchase of our securities and must have received the purchaser’s written consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, the rules require the delivery, prior to the first transaction, of a risk disclosure document relating to the penny stock. A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, and current quotations for the security. Finally, monthly statements must be sent to the purchaser disclosing recent price information for the penny stocks. Consequently, these rules may restrict the ability of broker-dealers to trade or maintain a market in our common stock and may affect the ability of shareholders to sell their shares.

Holders

As of June 30, 2020, there were approximately 630 shareholders of record holding 20,236,021,836 shares of common stock. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Holders of the common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock.

Table of Contents

Dividends

The Company has not paid any dividends on its common stock. The Company current intends to retain any earnings for use in its business, and therefore does not anticipate paying cash dividends in the foreseeable future.

Securities Authorized Under Equity Compensation Plans

The following table lists the securities authorized for issuance under any equity compensation plans approved by our shareholders and any equity compensation plans not approved by our shareholders as of June 30, 2020. This chart also includes individual compensation agreements.

EQUITY COMPENSATION PLAN INFORMATION
Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)		Weighted-average exercise price of outstanding options, warrants and rights (b)		Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)
Equity compensation plans approved by security holders		0	$	0.00		0
Equity compensation plans not approved by security holders		0	$	0.00		0
Total		0	$	0.00		0

Company repurchases of common stock during the year ended June 30, 2020

None

Performance Graphic

This item is not required to provide a performance graph since it is a “smaller reporting company” as defined in Exchange Act Regulation S-K Rule 10(f).

Share issuances in year ended June 30, 2020

All share issuances have been previously reported.

ITEM 6. SELECTED FINANCIAL DATA

This item is inapplicable because we are a “smaller reporting company” as defined in Exchange Act Rule 12b-2.

Table of Contents

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Forward Looking Statement Notice

This Current Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as “anticipate,” “expect,” “intend,” “plan,” “will,” “we believe,” “believes,” “management believes” and similar language. Except for the historical information contained herein, the matters discussed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this report are forward-looking statements that involve risks and uncertainties. The factors listed in the section captioned “Risk Factors,” as well as any cautionary language in this report; provide examples of risks, uncertainties and events that may cause our actual results to differ materially from those projected. Except as may be required by law, we undertake no obligation to update any forward-looking statement to reflect events after the date of this Form 10-K.

History and Organization

America Great Health, formerly Crown Marketing, is a Wyoming corporation (the “Company”). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.

On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.

On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.

On June 14, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China.

Overview of Business

The Company under the new management will focus its business in the health related industry. The Company’s Chairman and president, Mike Wang, is the owner of several health related businesses below with which The Company is evaluating the possibilities of forming several JVs. The Company might effectuate the JVs using stocks.

H&BG. It is a California company in the business of R &D and sale of vitamins and nutritional supplements. It owns more than 20 formulas and engages contract manufacturers to make these products. The company has built up sales records both in the US as well as in China. On January 4, 2018, the Company entered into a Stock Purchase Agreement with H&BG (the “Seller”) to purchase 51% of common shares of the Seller, for $765,000, which consisted of 63,750,000 outstanding shares of the Company’s common stock at $0.012 per share. On April 5, 2018, the Company entered into a Rescission Agreement (the “Rescission Agreement”) with the seller to rescind the transactions set forth in the Stock Purchase Agreement prior to the transaction closing.

Table of Contents

Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare , LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also provide Total Solution Services related with the use of the Equipment.

Sales Agreement between Mike Wang and Dr. William Fang for the marketing and sales of Dr. Fang’s early detection system of Cardio Vascular diseases. The device provides unique 3D imaging for the Cardio Vascular conditions for patients and has already won approval of US FDA. It has very positive significance in helping preventing heart attacks, which are the number one killer in the US as well as in the world.

Pursuant to the JV Agreement, AAGH CA and Bona each own 49% and 51% of Pomeikang, respectively, and AAGH California has the veto right to stop the majority shareholder’s decision. AAGH CA will contribute the initial products supply in equivalent of cash amount of RMB 2.45 million ($368,000) to Pomeikang and Bona will contribute any required operating capital, experienced sales team, promotional effort, and customer services to ensure normal day to day operation of Pomeikang. Bona will also be responsible for acquiring any required government permits, sales permits, and business licenses for Pomeikang.

At December 31, 2018, the Company decided to no longer participate in Pomeikang’s operations. On April 1, 2019, AAGH California transferred its 49% ownership to Bona for $1.

On May 21, 2018, the Company, entered into an Exclusive Oversea Distribution Agreement (the “Agreement”) with Foshan Wanshunbao Technology Co., Ltd. (“Wanshunbao”), a mainland China based company. According to the Agreement, Wanshunbao wishes to promote and develop overseas sales channels for its unique “Mysteries Fruit” tea and related products worldwide. The Company is appointed as Wanshunbao’s exclusive distributor to market and sell the “Mysteries Fruit” herbal tea and related products in geographic areas covers all over the world except mainland China.

In the past 20 years, Wangshunbao has dedicated to improve its R&D, and production of the unique “Mysteries Fruit” and related supplemental products, currently, Wangshunbao has developed a leading role in this industry, and is in the process of expanding its business model worldwide to a 10 billion RMB ($1.5 billion) industry chain. To achieve that goal, Wangshunbao’s management team had been actively seeking a qualified international distributor and business partner to execute its expansion plan.

The company is negotiating an acquisition intention with Hongkong Pure Aesthetics Biotechnology Limited, which holds several patents in stem cell. The patents are valued at nearly $59 million.

The Company is discussing the possibility of establishing a joint venture in California with an individual who has nearly ten years experiences in health products market.

Table of Contents

The Company is also planning to conduct additional acquisitions. Mike Wang has approached several health related companies in China and met the management of potential acquisition targets. Rapid economic advances in China in the last 30 years have greatly improved the living standards in China. This in turn brings demand in healthcare products and services. The Company feels strongly that despite the challenges of cross border business, it might be able to acquire some good growth companies and bring good values to our stockholders.

As inherent with any new business development, there are risks involved in such endeavor. For all the healthcare related businesses afore-mentioned, the Company is evaluating what kind of risks we are facing. The Company notices that vitamin and nutrition supplement business is a highly competitive market and faces multiple regulatory monitoring. The compliance challenge is constant. Regarding proton treatment sales, the device is very expensive and for such large ticket item, the procurement process can be long and arduous. The sale of cardio vascular device also has its challenges. The device is not well known and the acceptance of the use requires major efforts in educating not only the medical professionals but also consumers. This would demand financial as well as other resources. Although the Company is making some progress in its Merger and Acquisition efforts, any results, are still not certain.

Critical Accounting Policies and Estimates

Estimates

The preparation of these consolidated financial statements (“CFS”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others, the fair value of shares of common stock issued for services. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

Recent Accounting Pronouncements

See Footnote 2 of the financial statements for a discussion of recently issued accounting standards.

Results of Operations

Results of Operations for the year ended June 30, 2020 compared to the year ended June 30, 2019.

There was no revenue and cost of sales for the year ended June 30, 2020.

Operating expenses for the year ended June 30, 2020 and 2019 was $48,256 and $46,771, respectively. The slight increase in the year ended June 30, 2020 was mainly due to the higher professional fee.

Our net loss for the year ended June 30, 2020 and 2019 was $51,916 and $65,043, respectively. The decrease in net loss in the year ended June 30, 2020 was mainly due to no loss on investment from the JV and no loss on disposal of JV investment, as wells as the gross profit generated by sales, partly offset by the higher operating expenses.

Liquidity and Capital Resources

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.

The accompanying CFS were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2020, the Company recorded a net loss of $ $51,916, used cash to fund operating activities of $39,559, and at June 30, 2020, had a shareholders’ deficit of $215,007. For the year ended June 30, 2019, the Company recorded a net loss of $65,043, used cash to fund operating activities of $27,792. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Table of Contents

The new management’s plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations.

Our cash needs for the year ended June 30, 2020 were primarily met by loans and advances from current majority shareholder. As of June 30, 2020, we had cash balance of $166. Our new majority shareholders will need to provide all of our working capitals going forward.

Primarily as a result of our recurring losses and our lack of liquidity, we received a report from our independent registered public accounting firm for our financial statements for the year ended June 30, 2020 that includes an explanatory paragraph describing the uncertainty as to our ability to continue as a going concern.

Financial Position

As of June 30, 2020, we had $166 in cash, negative working capital of $215,007 and an accumulated deficit of $3,286,642.

Contractual Obligations and Off-Balance Sheet Arrangements

We do not have any contractual obligations or off balance sheet arrangements.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Our financial statements appear beginning on page F-1in this Form 10-K.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Based upon an evaluation of the effectiveness of our disclosure controls and procedures performed by our Chief Executive Officer as of the end of the period covered by this report, our Chief Executive Officer concluded that our disclosure controls and procedures have not been effective as a result of a weakness in the design of internal control over financial reporting identified below.

As used herein, “disclosure controls and procedures” mean controls and other procedures of our company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Table of Contents

Management’s Annual Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting (“ICFR”), as such term is defined in Exchange Act Rule 13a-15(f) under the Securities Exchange Act of 1934. Our Chief Executive Officer/Chief Accounting Officer conducted an evaluation of the effectiveness of our ICFR based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO 2013”). Based on management’s evaluation under the framework, management has concluded that our ICFR was not effective as of June 30, 2020.

We identified material weaknesses in our ICFR primarily attributable to (i) lack of segregation of incompatible duties; and (ii) insufficient Board of Directors representation. These weaknesses are due to our inadequate staffing during the period covered by this report and our lack of working capital to hire additional staff. Management has retained an outside, independent financial consultant to record and review all financial data, as well as prepare our financial reports, in order to mitigate this weakness. Although management will periodically re-evaluate this situation, at this point it considers that the risk associated with such lack of segregation of duties and the potential benefits of adding employees to segregate such duties are not cost justified. We intend to hire additional accounting personnel to assist with financial reporting as soon as our finances will allow.

This annual report does not include an attestation report of our registered public accounting firm regarding ICFR. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report.

ITEM 9B. OTHER INFORMATION

None.

Table of Contents

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Directors and Executive Officers

The members of the Board of Directors (“BOD”) of the Company serve until the next annual meeting of stockholders, or until their successors have been elected. The officers serve at the pleasure of the BOD. The following are the directors, executive officers and key employees of the Company.

Our management team is headed by experienced Chief Executive Officer Mike Wang, who was elected on March 1, 2017.

Mike Wang, age 67, has been working in the health supplements business for about 20 years. He is the President of America Great Health. And he is also the vice-president of the American Nutrition and Health Association in Los Angeles, California.

Code of Ethics

The Company has not adopted a code of ethics which applies to the chief executive officer, or principal financial and accounting officer, because of our current low level of operations as a public entity. The Company intends to adopt a code of ethics in near future.

Audit Committee Financial Expert

The Company does not have either an Audit Committee or a financial expert on the BOD. The BOD believes that obtaining the services of an audit committee financial expert is not economically rational at this time in light of the costs associated with identifying and retaining an individual who would qualify as an audit committee financial expert, the limited scope of our operations and the relative simplicity of our financial statements and accounting procedures.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act requires the Company's officers, directors and persons who own more than 10 percent of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Officers, directors and ten percent stockholders are required by regulation to furnish the Company with copies of all Section 16(a) forms they file. During the year ended June 30, 2020, the Company believes that all such persons failed to file the reports required by Section 16(a) of the Exchange Act, including Forms 3, 4 and 5. Based on representations submitted by such people, the Company does not believe that such individuals purchased or sold any Common Stock of the Company through public exchange during the year ended June 30, 2020.

ITEM 11. EXECUTIVE COMPENSATION

Executive Officers and Directors

The following tables set forth certain information about compensation paid, earned or accrued for services by (i) the Company’s Chief Executive Officer in the years ended June 30, 2020 and 2019 (“Named Executive Officers”):

Name and Principal Position	Year	Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensation ($)		Nonqualified Deferred Compensation ($)		All Other Compensation ($)		Total ($)
Mike Wang Chief Executive/Chief Financial Officer	2020		-		-		-		-		-		-		-		-

Mike Wang Chief Executive/Chief Financial Officer	2019		-		-		-		-		-		-		-		-

Table of Contents

Employment Contracts

We currently do not have any written employment agreements with our executive officers.

Director Compensation

Our directors currently serve without compensation.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Beneficial Ownership

The following table sets forth, as of the date of this Report the outstanding common stock of the Company owned of record or beneficially by each person who owned of record, or was known by the Company to own beneficially, more than 5% of the Company’s 20,236,021,836 shares of common stock issued and outstanding, and the name and shareholdings of each director and all of the executive officers and directors as a group:

CERTAIN BENEFICIAL OWNERS
Name	Office	Amount and nature of beneficial owner (1)		Percent of class

Mike Wang (2)	CEO, CFO, Director		8,565,142,133		42.33	%

All officer and directors as a group (1 person)	N/A		8,565,142,133		42.33	%

(1)	Except as otherwise noted, shares are owned beneficially and of record, and such record shareholder has sole voting, investment and dispositive power.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

During the year ended June 30, 2020, the Company's current majority shareholder advanced $121,840 to the Company as working capital and the Company repaid $82,217 to the shareholder. As of June 30, 2020 and 2019, the Company owed its current majority shareholder of $168,028 and $128,404 respectively. The advances are non-interest bearing and are due on demand.

The Company currently is using a premise for free, the premises is leased by a company owned by its current majority shareholder.

Director Independence

Currently, the Company does not have any independent directors. Since the Company’s Common Stock is not currently listed on a national securities exchange, we have used the definition of “independence” of The NASDAQ Stock Market to make this determination.

Under NASDAQ Listing Rule 5605(a)(2), an "independent director" is a "person other than an officer or employee of the company or any other individual having a relationship which, in the opinion of the company's board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director."

We do not currently have a separately designated audit, nominating or compensation committee. However, we do intend to comply with the independent director and committee composition requirements in the future.

Table of Contents

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The following table sets forth the fees paid by the Company for professional services rendered for the audits of the annual financial statements and fees billed for other services rendered by its principal accountants:

Type of Services Rendered	2020		2019

Audit Fees	$	20,000	$	20,000
Audit-Related Fees	$	-	$	-
Tax Fees	$	-	$	-
All Other Fees	$	-	$	-

Pre-approval Policies

We do not have a standing audit committee currently serving and as a result our BOD performs the duties of an audit committee. Our BOD evaluates and approves, in advance, the scope and cost of the engagement of an accounting firm before the accounting firm renders audit and non-audit services. We do not rely on pre-approval policies and procedures.

Table of Contents

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) Financial Statements.

Report of Independent Registered Public Accounting Firm	F-1

Consolidated Balance Sheets as of June 30, 2020 and 2019	F-2

Consolidated Statements of Operations for the Years Ended June 30, 2020 and 2019	F-3

Consolidated Statements of Shareholders’ Deficit for the Years Ended June 30, 2020 and 2019	F-4

Consolidated Statements of Cash Flows for the Years Ended June 30, 2020 and 2019	F-5

Notes to Consolidated Financial Statements	F-6

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

America Great Health and Subsidiaries

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of America Great Health and Subsidiaries (the “Company”) as of June 30, 2020 and 2019, and the related statements of operations, stockholders' deficit, and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2020, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States.

Going Concern Matter

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement, whether due to error fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.

Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ TAAD, LLP

We have served as the Company’s auditor since 2020, and we previously served as the Company’s auditor from 2016 through 2018

Diamond Bar, California

July 12, 2021

F-1

Table of Contents

America Great Health and Subsidiaries (fka “ Crown Marketing”)
Consolidated Balance Sheets

	June 30,			June 30,
	2020			2019

ASSETS
CURRENT ASSETS
Cash	$	166		$	102
Inventory		1,141			-
Other receivable		2,587			-

TOTAL CURRENT ASSETS		3,894			102
TOTAL ASSETS	$	3,894		$	102

LIABILITIES AND SHAREHOLDERS' DEFICIT

CURRENT LIABILITIES
Accounts payable and accrued expense	$	49,273		$	38,900
Income tax payable		1,600			800
Due to related party		168,028			128,404

TOTAL CURRENT LIABILITIES		218,901			168,104

SHAREHOLDERS' DEFICIT

Redeemable, convertible preferred stock, 10,000,000 shares authorized; Series A voting preferred stock, zero shares issued and outstanding		-			-
Common stock, no par value, unlimited shares authorized; 20,236,021,836 and 20,236,021,836 shares issued and outstanding		-			-
Additional paid-in capital		3,071,635			3,066,724
Accumulated deficit		(3,286,642	)		(3,234,726	)
TOTAL SHAREHOLDERS' DEFICIT		(215,007	)		(168,002	)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$	3,894		$	102

The accompanying notes are an integral part of these consolidated financial statements.

F-2

Table of Contents

America Great Health and Subsidiaries (fka “ Crown Marketing”)
Consolidated Statements of Operations

	Year Ended June 30,
	2020			2019


Sales	$	5,474		$	-

Cost of goods sold		3,369			-

Gross profit		2,105			-

Selling, general and administrative expenses
Professional fee		34,255			33,507
Other		14,001			13,264
		48,256			46,771

Loss from operations		(46,151	)		(46,771	)

Other income (expenses)
Interest expense		(4,965	)		(4,494	)
Loss on investment		-			(966	)
Loss on disposal of investment		-			(12,012	)
		(4,965	)		(17,472	)

Loss before income tax		(51,116	)		(64,243	)

Income tax provision		800			800

NET LOSS	$	(51,916	)	$	(65,043	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.00	)	$	(0.00	)

WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED		20,236,021,836			20,236,021,836

The accompanying notes are an integral part of these consolidated financial statements.

F-3

Table of Contents

America Great Health and Subsidiaries (fka “Crown Marketing”) Consolidated Statement of Shareholders' Deficit

	Preferred Stock				Common Stock				Additional		Accumulated
	Shares		Amount		Shares		Amount		Paid-in Capital		Deficit			Total

Balance, June 30, 2018		-	$	-		20,236,021,836	$	-	$	3,062,230	$	(3,169,683	)	$	(107,453	)

Imputed Interest		-		-		-		-		4,494		-			4,494
Net loss		-		-		-		-		-		(65,043	)		(65,043	)

Balance, June 30, 2019		-		-		20,236,021,836		-		3,066,724		(3,234,726	)		(168,002	)

Imputed Interest		-		-		-		-		4,911		-			4,911
Net loss		-		-		-		-		-		(51,916	)		(51,916	)

Balance, June 30, 2020		-	$	-		20,236,021,836	$	-	$	3,071,635	$	(3,286,642	)	$	(215,007	)

The accompanying notes are an integral part of these consolidated financial statements.

F-4

Table of Contents

America Great Health and Subsidiaries (fka “ Crown Marketing”)
Consolidated Statements of Cash Flows

	Year Ended June 30
	2020			2019

Cash Flows from Operating Activities
Net loss	$	(51,916	)	$	(65,043	)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on investment		-			966
Loss on disposal of investment		-			12,012
Imputed interest		4,911			4,494
Changes in operating Assets and Liabilities:
Inventory		(1,141	)		-
Other receivable		(2,587	)		100
Accounts payable and accrued expense		10,374			18,879
Income tax payable		800			800
Net cash used in operating activities		(39,559	)		(27,792	)

Cash Flows from Financing Activities
Advances from related party		121,840			29,379
Repayment to related party		(82,217	)		(1,500	)
Net cash provided by financing activities		39,623			27,879

Net increase (decrease) in cash		64			87

Cash beginning of period		102			15
Cash end of period	$	166		$	102

Interest paid	$	-		$	-
Taxes paid	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements.

F-5

Table of Contents

AMERICA GREAT HEALTH AND SUBSIDIARIES

(FORMERLY KNOWN AS CROWN MARKETING)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020 AND 2019

NOTE 1 – NATURE OF BUSINESS

History and Organization

On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.

On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.

Going Concern

The accompanying consolidated financial statements (“CFS”) were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2020, the Company recorded a net loss of $51,916, used cash to fund operating activities of $39,559, and at June 30, 2020, had a shareholders’ deficit of $215,007. These factors create substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations.

Our cash needs for the 12 months ended June 30, 2020 were primarily met by loans and advances from current majority shareholder. As of June 30, 2020, we had a cash balance of $166. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Basis of Consolidation

The CFS includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California and Meizhong Health Industry Development Co., Ltd, Intercompany transactions and accounts were eliminated in consolidation.

F-6

Table of Contents

Estimates

The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services. Actual results could differ from those estimates.

Revenues

Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, is recognized in a manner that reasonably reflects the delivery of the Company’s products and services to customers in return for expected consideration and includes the following elements:

●

executed contract(s) with customers that the Company believes is legally enforceable;

●

identification of performance obligation in the respective contract;

●

determination of the transaction price for each performance obligation in the respective contract;

●

allocation of the transaction price to each performance obligation; and

●

recognition of revenue only when the Company satisfies each performance obligation.

Inventories

Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances.

Fair Value Measurements

Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s assumptions.

The Company is required to use observable market data if available without undue cost and effort.

The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.

Loss per Share

Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended June 30, 2020 and 2019, as there are no potential shares outstanding that would have a dilutive effect.

Income Taxes

Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of June 30, 2020 and 2019.

F-7

Table of Contents

The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.

Recent Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

NOTE 3 – RELATED PARTY TRANSACTIONS

Currently the Company is using a premise for free, the premises is leased by a company owned by its current majority shareholder.

NOTE 4 – SHAREHOLDERS’ DEFICIT

At June 30, 2020 and 2019, the Company had 20,236,021,836 shares issued and outstanding.

NOTE 5 – JOINT VENTURE

On March 5th, 2018, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Sino-foreign Co-operative Joint Venture Contract (the “JV Agreement”) with Guangzhou Bona Biotechnology Co., Ltd. (“Bona”) pursuant to which the parties established a JV, Pomeikang Biotechnology (Guangzhou) Co., Ltd. (“Pomeikang”) to promote and develop sales channels for health and cosmetics related products supplied by AAGH California in the mainland of the People’s Republic of China, the Hong Kong Special Administration Region and the Macau Special Administration Region (together, the “China Market”).

Pursuant to the JV Agreement, AAGH California and Bona will each own 49% and 51% of the JV Company, respectively, and AAGH California has the veto right to the majority shareholder’s decision. The equity method has been used for this JV. AAGH California will contribute the initial products supply in equivalent of cash amount of RMB 2.45 million to the JV Company and Bona will contribute any required operating capitals, experienced sales team, promotional effort, and customer services to ensure normal day to day operation of the JV Company. Bona will also be responsible for acquiring any required government permits, sales permits, and business licenses for the JV Company.

The following table summarizes the income statement of Pomeikang.

	From date of equity investment to 12/31/2018

Sales	$	20,740
Gross profit		13,739
Net loss		(2,803	)
49% share		(1,373	)

F-8

Table of Contents

The following table provides the summary of balance sheet information for Pomeikang.

	As of December 31, 2018

Total assets	$	20,565
Net assets		20,565
49% ownership		10,077
Ending balance of investment account before written off		12,012
Difference		(1,932	)

The difference of $1,932 was mainly due to the effect of exchange rate.

There was no operation during the period from October 1, 2018 to December 31, 2018, therefore at December 31, 2018, the Company decided to no longer participate in Pomeikang’s operations. As a result, a loss on disposal of investment of $12,012 was recorded at December 31, 2018. On April 1, 2019, AAGH California transferred its 49% ownership to Bona for $1.

NOTE 6 – INCOME TAXES

Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards.

As of June 30, 2020, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with the deferred tax asset. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset.

The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes for the years ended June 30, 2020 and 2019 as follows:

	Year Ended June 30,
	2020			2019

Income tax benefit at federal statutory rate		21	%		21	%
State tax, net of fed effect		7	%		7	%
Change in valuation allowance		-28	%		-28	%
		-	%		-	%

The components of deferred taxes consist of the following at June 30, 2020 and 2019:

	June 30, 2020			June 30, 2019

Net operating loss carryforwards	$	238,591		$	905,723
Less: valuation allowance		(238,591	)		(905,723	)
Net deferred tax assets	$	-		$	-

As of June 30, 2020, the Company had federal and California income tax net operating loss carryforwards of $852,111 . These net operating losses originating in tax years beginning prior to Jan. 1, 2018 will begin to expire 20 years from the date the tax returns are filed. The net operating losses originating in tax years beginning after Jan. 1, 2018 will be carry forwarded indefinitely.

F-9

Table of Contents

NOTE 8 – SUBSEQUENT EVENTS

On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s annual report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology (with estimated value of USD $29.8 million) to the JV Company as its capital contribution, to account for 40% equity ownership.

1) Shares issued for merger & acquisition

Investment in Brilliant Healthcare Limited

Investment in Imedipus Inc.

On January 30, 2020, the Company and Imediplus Inc. (“Imediplus”), a leading medical institution in Taiwan, entered into a Cooperation Agreement, in which the Company agreed to acquire 48% of the equity of Imediplus, as consideration, the Company shall pay $1,000,000 and issue 662,000,000 common shares to Imediplus. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members.

As of June 30, 2021, the Company has not completed its financial and legal due diligence and has not consummated the acquisition of Imediplus.

On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus.

Investment in Purecell Group

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell") in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at market price of $0.14 per share.

On May 11, 2021, Aussie Produce PTY LTD ("AP") signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP.

2) Shares issued for stock compensation

On January 22, 2021, the Company issued an aggregate of 48,220,124 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.06 per share.

F-10

Table of Contents

On March 10, 2021, the Company issued an aggregate of 79,362,534 shares of common stock to 54 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.13 per share.

On April 7, 2021, the Company issued an aggregate of 6,621,905 shares of common stock to 12 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.13 per share.

On May 5, 2021, the Company issued an aggregate of 1,300,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share.

On May 18, 2021, the Company issued an aggregate of 7,140,000 shares of common stock to 5 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share.

On May 18, 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company of relevant theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology; Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. As consideration, the Company agreed to grant 8 million shares of AAGH common stock to Dr. Tsai along with certain monthly compensations and sales bonus.

On May 26, 2021, the Company issued an aggregate of 2,450,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.15 per share.

On June 18, 2021, the Company issued an aggregate of 11,300,000 shares of common stock to 22 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.16 per share.

3) Shares issued for loan as collateral

On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.04 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on April 27, 2021.

On June 18, 2021, the Company issued an aggregate of 3,050,000 shares to 6 unrelated parties as collateral for loans of $290,000. The loans have an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 3, 2021.

On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date , the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 4, 2021.

F-11

Table of Contents

(b) Exhibits. The following exhibits of the Company are included herein.

2. Agreement and Plan of Reorganization

2.1 Agreement and Plan of Reorganization between the Company and Okra Energy, Inc. dated December 2, 2013.(4)

3. Certificate of Incorporation and Bylaws

3.1. Articles of Incorporation (1)*

3.2 Articles of Merger (2)

3.3 Bylaws(1)

3.4 Amended and Restated Articles of Incorporation, as filed June 24, 2016(5)

3.5 Amendment to Articles of Incorporation increasing authorized Series A Preferred, August 20, 2016(5)

10. Material Contracts

10.1 Promissory Note to Strategic Global Resources, Ltd. (3)

10.2 Promissory Note to Farrington Pharmaceuticals, LLC (3)

10.3 Lease Agreement between Okra Energy, Inc. and Temple CB, LLC (4)

21. Subsidiaries of the registrant – Okra Energy, a California corporation and Crown Laboratory, Inc. Crown Mobile is a California corporation which is 50% owned by the Company. No trade names are employed.

31.1 Certification by the Principal Executive Officer and Principal Accounting and Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1. Certifications by the Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* The Company had filed an amendment to its Articles of Incorporation to change the name to “Okra, Inc.’ but this amendment was reversed in an additional amendment filed with the Secretary of State. The name of the Company continues to be “Crown Marketing.”

All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.

(1) Filed with original registration statement.

(2) Filed with amendment no. 1.

(3) Filed with the Annual Report on Form 10-K for the year ended June 30, 2013.

(4) Filed with Current Report on Form 8-K dated December 2, 2013.

(5) Filed with the Annual Report on Form 10-K for the year ended June 30, 2016.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMERICA GREAT HEALTH

Date: July 12, 2021

/s/ Mike Wang

Mike Wang, Chief Executive Officer,

Chief Financial Officer, Secretary and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Date: July 12, 2021

/s/ Mike Wang

Mike Wang, Chief Executive Officer,

Chief Financial Officer, Secretary and Director

EX-31.1 2 ex_261991.htm EXHIBIT 31.1 ex_261991.htm

EXHIBIT 31.1

CERTIFICATION

I, Mike Wang, certify that:

1. I have reviewed this quarterly report on Form 10-K of America Great Health;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated: July 12, 2021	By:	/s/ Mike Wang
		Mike Wang
		Chief Financial Officer, Secretary and Director

EX-32.1 3 ex_261992.htm EXHIBIT 32.1 ex_261992.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of America Great Health (the “Company”) on Form 10-K for the year ending June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mike Wang, President and Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: July 12, 2021	By:	/s/ Mike Wang
		Mike Wang
		Chief Financial Officer, Secretary and Director

EX-101.INS 4 aagh-20200630.xml XBRL INSTANCE DOCUMENT 0001098009 2019-07-01 2020-06-30 0001098009 2021-07-12 0001098009 2018-12-31 0001098009 2020-06-30 0001098009 2019-06-30 0001098009 2018-07-01 2019-06-30 0001098009 us-gaap:CommonStockMember 2018-06-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001098009 us-gaap:RetainedEarningsMember 2018-06-30 0001098009 2018-06-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2019-06-30 0001098009 us-gaap:RetainedEarningsMember 2018-07-01 2019-06-30 0001098009 us-gaap:CommonStockMember 2019-06-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001098009 us-gaap:RetainedEarningsMember 2019-06-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2020-06-30 0001098009 us-gaap:RetainedEarningsMember 2019-07-01 2020-06-30 0001098009 us-gaap:CommonStockMember 2020-06-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001098009 us-gaap:RetainedEarningsMember 2020-06-30 0001098009 2017-01-19 2017-01-19 0001098009 aagh:GuangzhouBonaNiotechnologyCoLtdMember 2018-06-30 0001098009 2017-07-01 2018-06-30 0001098009 2017-10-01 2018-12-31 0001098009 aagh:GuangzhouBonaNiotechnologyCoLtdMember 2019-04-01 0001098009 aagh:GuangzhouBonaNiotechnologyCoLtdMember 2019-04-01 2019-04-01 0001098009 us-gaap:CorporateJointVentureMember 2018-03-05 2018-12-31 0001098009 us-gaap:CorporateJointVentureMember 2018-12-31 0001098009 us-gaap:CorporateJointVentureMember us-gaap:SubsequentEventMember 2020-12-07 2020-12-07 0001098009 us-gaap:CorporateJointVentureMember us-gaap:SubsequentEventMember 2020-12-07 0001098009 aagh:BrilliantHealthcareLimitedMember us-gaap:CorporateJointVentureMember us-gaap:SubsequentEventMember 2020-12-07 0001098009 aagh:ImediplusIncMember 2020-01-30 0001098009 aagh:ImediplusIncMember 2020-01-30 2020-01-30 0001098009 aagh:ImediplusIncMember us-gaap:SubsequentEventMember 2021-04-06 2021-04-06 0001098009 aagh:ImediplusIncMember us-gaap:SubsequentEventMember 2021-04-06 0001098009 aagh:PurecellGroupMember 2020-06-30 0001098009 aagh:PurecellGroupMember 2020-06-30 2020-06-30 0001098009 aagh:PurecellGroupMember us-gaap:SubsequentEventMember 2021-04-06 2021-04-06 0001098009 aagh:PurecellGroupMember us-gaap:SubsequentEventMember 2021-04-06 0001098009 aagh:PurecellGroupMember us-gaap:SubsequentEventMember aagh:AussieProducePTYLTDMember 2021-05-11 2021-05-11 0001098009 aagh:PurecellGroupMember us-gaap:SubsequentEventMember aagh:AussieProducePTYLTDMember 2021-05-11 0001098009 aagh:PurecellGroupMember us-gaap:SubsequentEventMember 2021-05-11 2021-05-11 0001098009 us-gaap:SubsequentEventMember 2021-01-22 2021-01-22 0001098009 us-gaap:SubsequentEventMember 2021-01-22 0001098009 us-gaap:SubsequentEventMember 2021-03-10 2021-03-10 0001098009 us-gaap:SubsequentEventMember 2021-03-10 0001098009 us-gaap:SubsequentEventMember 2021-04-07 2021-04-07 0001098009 us-gaap:SubsequentEventMember 2021-04-07 0001098009 us-gaap:SubsequentEventMember 2021-05-05 2021-05-05 0001098009 us-gaap:SubsequentEventMember 2021-05-05 0001098009 us-gaap:SubsequentEventMember 2021-05-18 2021-05-18 0001098009 us-gaap:SubsequentEventMember 2021-05-18 0001098009 aagh:DrTsaiMember us-gaap:SubsequentEventMember 2021-05-18 2021-05-18 0001098009 us-gaap:SubsequentEventMember 2021-05-26 2021-05-26 0001098009 us-gaap:SubsequentEventMember 2021-05-26 0001098009 us-gaap:SubsequentEventMember 2021-06-18 2021-06-18 0001098009 us-gaap:SubsequentEventMember 2021-06-18 0001098009 aagh:Loan1Member us-gaap:SubsequentEventMember 2021-05-05 2021-05-05 0001098009 aagh:Loan1Member us-gaap:SubsequentEventMember 2021-05-05 0001098009 aagh:Loan2Member us-gaap:SubsequentEventMember 2021-06-18 2021-06-18 0001098009 aagh:Loan2Member us-gaap:SubsequentEventMember 2021-06-18 0001098009 aagh:Loan3Member us-gaap:SubsequentEventMember 2021-06-18 2021-06-18 0001098009 aagh:Loan3Member us-gaap:SubsequentEventMember 2021-06-18 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:CNY false --06-30 FY 2020 2020-06-30 10-K 0001098009 Yes false Non-accelerated Filer No America Great Health false true No No 21070866399 0

166

102

1141

2587

3894

102

3894

102

49273

38900

1600

800

168028

128404

218901

168104

10000000

20236021836

3071635

3066724

-3286642

-3234726

-215007

-168002

3894

102

5474

3369

2105

34255

33507

14001

13264

48256

46771

-46151

-46771

4965

4494

-966

-12012

-4965

-17472

-51116

-64243

800

-51916

-65043

0.00

20236021836

3062230

-3169683

-107453

4494 4494

-65043

20236021836

3066724

-3234726

4911 4911

-51916

20236021836

3071635

-3286642

-51916

-65043

1141

2587

-100

10374

18879

800

-39559

-27792

121840

29379

82217

1500

39623

27879

102

166

<div style="font-family: "Times New Roman"; font-size: 10pt; "> NOTE 1 – NATURE OF BUSINESS History and Organization America Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang.  In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations. On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health. On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California. On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China. Going Concern  The accompanying consolidated financial statements (“CFS”) were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2020, the Company recorded a net loss of $51,916, used cash to fund operating activities of $39,559, and at June 30, 2020, had a shareholders’ deficit of $215,007. These factors create substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations. Our cash needs for the 12 months ended June 30, 2020 were primarily met by loans and advances from current majority shareholder.  As of June 30, 2020, we had a cash balance of $166. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder. </div>

16155746000

100

<div style="font-family: Times New Roman; font-size: 10pt; "> NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Basis of Consolidation The CFS includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California and Meizhong Health Industry Development Co., Ltd, Intercompany transactions and accounts were eliminated in consolidation. Estimates  The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services. Actual results could differ from those estimates. Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, is recognized in a manner that reasonably reflects the delivery of the Company’s products and services to customers in return for expected consideration and includes the following elements: <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:top;width:3.3%;"> </td> <td style="vertical-align:top;width:3.3%;"> ● </td> <td style="vertical-align:top;width:auto;"> executed contract(s) with customers that the Company believes is legally enforceable; </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:top;width:3.3%;"> </td> <td style="vertical-align:top;width:3.3%;"> ● </td> <td style="vertical-align:top;width:auto;"> identification of performance obligation in the respective contract; </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:top;width:3.3%;"> </td> <td style="vertical-align:top;width:3.3%;"> ● </td> <td style="vertical-align:top;width:auto;"> determination of the transaction price for each performance obligation in the respective contract; </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:top;width:3.3%;"> </td> <td style="vertical-align:top;width:3.3%;"> ● </td> <td style="vertical-align:top;width:auto;"> allocation of the transaction price to each performance obligation; and </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:top;width:3.3%;"> </td> <td style="vertical-align:top;width:3.3%;"> ● </td> <td style="vertical-align:top;width:auto;"> recognition of revenue only when the Company satisfies each performance obligation. </td> </tr> </table> Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature. Loss per Share Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended June 30, 2020 and 2019, as there are no potential shares outstanding that would have a dilutive effect. Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of June 30, 2020 and 2019. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements.  </div>

<div style="font-family: Times New Roman; font-size: 10pt; "> Basis of Presentation The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).</div>

<div style="font-family: Times New Roman; font-size: 10pt; "> Basis of Consolidation The CFS includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California and Meizhong Health Industry Development Co., Ltd, Intercompany transactions and accounts were eliminated in consolidation.</div>

<div style="font-family: Times New Roman; font-size: 10pt; "> Estimates  The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services. Actual results could differ from those estimates</div>

<div style="font-family: Times New Roman; font-size: 10pt; "> Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, is recognized in a manner that reasonably reflects the delivery of the Company’s products and services to customers in return for expected consideration and includes the following elements: <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:top;width:3.3%;"> </td> <td style="vertical-align:top;width:3.3%;"> ● </td> <td style="vertical-align:top;width:auto;"> executed contract(s) with customers that the Company believes is legally enforceable; </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:top;width:3.3%;"> </td> <td style="vertical-align:top;width:3.3%;"> ● </td> <td style="vertical-align:top;width:auto;"> identification of performance obligation in the respective contract; </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:top;width:3.3%;"> </td> <td style="vertical-align:top;width:3.3%;"> ● </td> <td style="vertical-align:top;width:auto;"> determination of the transaction price for each performance obligation in the respective contract; </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:top;width:3.3%;"> </td> <td style="vertical-align:top;width:3.3%;"> ● </td> <td style="vertical-align:top;width:auto;"> allocation of the transaction price to each performance obligation; and </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tr> <td style="vertical-align:top;width:3.3%;"> </td> <td style="vertical-align:top;width:3.3%;"> ● </td> <td style="vertical-align:top;width:auto;"> recognition of revenue only when the Company satisfies each performance obligation.</td></tr></table></div>

<div style="font-family: Times New Roman; font-size: 10pt; "> Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.</div>

<div style="font-family: Times New Roman; font-size: 10pt; "> Loss per Share Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended June 30, 2020 and 2019, as there are no potential shares outstanding that would have a dilutive effect.</div>

<div style="font-family: Times New Roman; font-size: 10pt; "> Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances.</div>

<div style="font-family: Times New Roman; font-size: 10pt; "> Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements</div>

<div style="font-family: Times New Roman; font-size: 10pt; "> NOTE 3 – RELATED PARTY TRANSACTIONS During the year ended June 30, 2020, the Company's current majority shareholder advanced $121,840 to the Company as working capital and the Company repaid $82,217 to the shareholder. As of June 30, 2020 and 2019, the Company owed its current majority shareholder of $168,028 and $128,404 respectively. The advances are non-interest bearing and are due on demand. Currently the Company is using a premise for free, the premises is leased by a company owned by its current majority shareholder. </div>

<div style="font-family: Times New Roman; font-size: 10pt; "> NOTE 5 – JOINT VENTURE On March 5th, 2018, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Sino-foreign Co-operative Joint Venture Contract (the “JV Agreement”) with Guangzhou Bona Biotechnology Co., Ltd. (“Bona”) pursuant to which the parties established a JV, Pomeikang Biotechnology (Guangzhou) Co., Ltd. (“Pomeikang”) to promote and develop sales channels for health and cosmetics related products supplied by AAGH California in the mainland of the People’s Republic of China, the Hong Kong Special Administration Region and the Macau Special Administration Region (together, the “China Market”). Pursuant to the JV Agreement, AAGH California and Bona will each own 49% and 51% of the JV Company, respectively, and AAGH California has the veto right to the majority shareholder’s decision. The equity method has been used for this JV. AAGH California will contribute the initial products supply in equivalent of cash amount of RMB 2.45 million to the JV Company and Bona will contribute any required operating capitals, experienced sales team, promotional effort, and customer services to ensure normal day to day operation of the JV Company. Bona will also be responsible for acquiring any required government permits, sales permits, and business licenses for the JV Company. The following table summarizes the income statement of Pomeikang. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1306" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1307" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> From date of equity investment to 12/31/2018 </td> <td id="new_id-1308" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td id="new_id-1309"> </td> <td id="new_id-1310"> </td> <td id="new_id-1311"> </td> <td id="new_id-1312"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 81%;"> Sales </td> <td id="new_id-1313" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1314" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-1315" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">20,740</td> <td id="new_id-1316" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Gross profit </td> <td id="new_id-1317" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1318" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1319" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">13,739</td> <td id="new_id-1320" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Net loss </td> <td id="new_id-1321" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1322" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1323" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(2,803</td> <td id="new_id-1324" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> ) </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> 49% share </td> <td id="new_id-1325" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1326" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1327" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(1,373</td> <td id="new_id-1328" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> ) </td> </tr> </table> The following table provides the summary of balance sheet information for Pomeikang. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1329" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1330" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As of December 31, 2018 </td> <td id="new_id-1331" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td id="new_id-1332"> </td> <td id="new_id-1333"> </td> <td id="new_id-1334"> </td> <td id="new_id-1335"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 81%;"> Total assets </td> <td id="new_id-1336" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1337" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-1338" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">20,565</td> <td id="new_id-1339" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Net assets </td> <td id="new_id-1340" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1341" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1342" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">20,565</td> <td id="new_id-1343" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> 49% ownership </td> <td id="new_id-1344" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1345" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1346" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10,077</td> <td id="new_id-1347" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Ending balance of investment account before written off </td> <td id="new_id-1348" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1349" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1350" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">12,012</td> <td id="new_id-1351" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Difference </td> <td id="new_id-1352" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1353" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1354" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(1,932</td> <td id="new_id-1355" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> ) </td> </tr> </table> The difference of $1,932 was mainly due to the effect of exchange rate. There was no operation during the period from October 1, 2018 to December 31, 2018, therefore at December 31, 2018, the Company decided to no longer participate in Pomeikang’s operations. As a result, a loss on disposal of investment of $12,012 was recorded at December 31, 2018. On April 1, 2019, AAGH California transferred its 49% ownership to Bona for $1. </div>

0.49

0.51

2450000

1932

-12012

0.49

<div style="font-family: "Times New Roman"; font-size: 10pt; "> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1306" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1307" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> From date of equity investment to 12/31/2018 </td> <td id="new_id-1308" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td id="new_id-1309"> </td> <td id="new_id-1310"> </td> <td id="new_id-1311"> </td> <td id="new_id-1312"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 81%;"> Sales </td> <td id="new_id-1313" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1314" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-1315" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">20,740</td> <td id="new_id-1316" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Gross profit </td> <td id="new_id-1317" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1318" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1319" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">13,739</td> <td id="new_id-1320" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Net loss </td> <td id="new_id-1321" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1322" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1323" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(2,803</td> <td id="new_id-1324" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> ) </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> 49% share </td> <td id="new_id-1325" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1326" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1327" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(1,373</td> <td id="new_id-1328" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> ) </td> </tr> </table><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1329" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1330" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As of December 31, 2018 </td> <td id="new_id-1331" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td id="new_id-1332"> </td> <td id="new_id-1333"> </td> <td id="new_id-1334"> </td> <td id="new_id-1335"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 81%;"> Total assets </td> <td id="new_id-1336" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1337" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-1338" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">20,565</td> <td id="new_id-1339" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Net assets </td> <td id="new_id-1340" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1341" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1342" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">20,565</td> <td id="new_id-1343" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> 49% ownership </td> <td id="new_id-1344" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1345" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1346" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10,077</td> <td id="new_id-1347" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Ending balance of investment account before written off </td> <td id="new_id-1348" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1349" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1350" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">12,012</td> <td id="new_id-1351" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Difference </td> <td id="new_id-1352" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1353" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1354" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(1,932</td> <td id="new_id-1355" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> ) </td> </tr> </table></div>

20740

13739

-2803

-1373

20565

10077

0.49

12012

-1932

<div style="font-family: Times New Roman; font-size: 10pt; "> NOTE 6 – INCOME TAXES Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards. As of June 30, 2020, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with the deferred tax asset. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset. The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes for the years ended June 30, 2020 and 2019 as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1356" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="6" id="new_id-1357" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Year Ended June 30, </td> <td id="new_id-1358" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1359" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1360" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2020 </td> <td id="new_id-1361" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-1362" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1363" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2019 </td> <td id="new_id-1364" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td id="new_id-1365"> </td> <td id="new_id-1366"> </td> <td id="new_id-1367"> </td> <td id="new_id-1368"> </td> <td id="new_id-1369"> </td> <td id="new_id-1370"> </td> <td id="new_id-1371"> </td> <td id="new_id-1372"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 62%;"> Income tax benefit at federal statutory rate </td> <td id="new_id-1373" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1374" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1375" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">21</td> <td id="new_id-1376" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> % </td> <td id="new_id-1377" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1378" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1379" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">21</td> <td id="new_id-1380" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> State tax, net of fed effect </td> <td id="new_id-1381" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1382" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1383" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7</td> <td id="new_id-1384" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> % </td> <td id="new_id-1385" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1386" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1387" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7</td> <td id="new_id-1388" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Change in valuation allowance </td> <td id="new_id-1389" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1390" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-1391" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-28</td> <td id="new_id-1392" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> % </td> <td id="new_id-1393" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1394" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-1395" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-28</td> <td id="new_id-1396" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1397" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1398" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td id="new_id-1399" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-1400" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> % </td> <td id="new_id-1401" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1402" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td id="new_id-1403" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-1404" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> % </td> </tr> </table> The components of deferred taxes consist of the following at June 30, 2020 and 2019: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1405" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1406" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, 2020 </td> <td id="new_id-1407" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-1408" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1409" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, 2019 </td> <td id="new_id-1410" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td id="new_id-1411"> </td> <td id="new_id-1412"> </td> <td id="new_id-1413"> </td> <td id="new_id-1414"> </td> <td id="new_id-1415"> </td> <td id="new_id-1416"> </td> <td id="new_id-1417"> </td> <td id="new_id-1418"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 62%;"> Net operating loss carryforwards </td> <td id="new_id-1419" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1420" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-1421" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">238,591</td> <td id="new_id-1422" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-1423" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1424" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-1425" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">905,723</td> <td id="new_id-1426" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Less: valuation allowance </td> <td id="new_id-1427" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1428" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-1429" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(238,591</td> <td id="new_id-1430" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> ) </td> <td id="new_id-1431" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1432" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-1433" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(905,723</td> <td id="new_id-1434" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> ) </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Net deferred tax assets </td> <td id="new_id-1435" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1436" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-1437" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-1438" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-1439" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1440" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-1441" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-1442" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table> As of June 30, 2020, the Company had federal and California income tax net operating loss carryforwards of $852,111 . These net operating losses originating in tax years beginning prior to Jan. 1, 2018 will begin to expire 20 years from the date the tax returns are filed. The net operating losses originating in tax years beginning after Jan. 1, 2018 will be carry forwarded indefinitely. </div>

852111000000

<div style="font-family: "Times New Roman"; font-size: 10pt; "> <div>The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes for the years ended June 30, 2020 and 2019 as follows:</div> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1356" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="6" id="new_id-1357" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Year Ended June 30, </td> <td id="new_id-1358" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1359" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1360" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2020 </td> <td id="new_id-1361" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-1362" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1363" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2019 </td> <td id="new_id-1364" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td id="new_id-1365"> </td> <td id="new_id-1366"> </td> <td id="new_id-1367"> </td> <td id="new_id-1368"> </td> <td id="new_id-1369"> </td> <td id="new_id-1370"> </td> <td id="new_id-1371"> </td> <td id="new_id-1372"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 62%;"> Income tax benefit at federal statutory rate </td> <td id="new_id-1373" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1374" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1375" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">21</td> <td id="new_id-1376" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> % </td> <td id="new_id-1377" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1378" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1379" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">21</td> <td id="new_id-1380" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> State tax, net of fed effect </td> <td id="new_id-1381" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1382" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1383" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7</td> <td id="new_id-1384" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> % </td> <td id="new_id-1385" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1386" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1387" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7</td> <td id="new_id-1388" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Change in valuation allowance </td> <td id="new_id-1389" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1390" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-1391" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-28</td> <td id="new_id-1392" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> % </td> <td id="new_id-1393" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1394" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-1395" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-28</td> <td id="new_id-1396" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> % </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1397" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1398" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td id="new_id-1399" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-1400" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> % </td> <td id="new_id-1401" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1402" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td id="new_id-1403" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-1404" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; white-space: nowrap;"> % </td> </tr> </table></div>

0.21

0.07

-0.28

<div style="font-family: "Times New Roman"; font-size: 10pt; "> <div>The components of deferred taxes consist of the following at June 30, 2020 and 2019:</div> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1405" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1406" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, 2020 </td> <td id="new_id-1407" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td id="new_id-1408" style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" id="new_id-1409" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> June 30, 2019 </td> <td id="new_id-1410" style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td id="new_id-1411"> </td> <td id="new_id-1412"> </td> <td id="new_id-1413"> </td> <td id="new_id-1414"> </td> <td id="new_id-1415"> </td> <td id="new_id-1416"> </td> <td id="new_id-1417"> </td> <td id="new_id-1418"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 62%;"> Net operating loss carryforwards </td> <td id="new_id-1419" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1420" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-1421" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">238,591</td> <td id="new_id-1422" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-1423" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1424" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td id="new_id-1425" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">905,723</td> <td id="new_id-1426" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Less: valuation allowance </td> <td id="new_id-1427" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1428" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-1429" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(238,591</td> <td id="new_id-1430" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> ) </td> <td id="new_id-1431" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1432" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td id="new_id-1433" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(905,723</td> <td id="new_id-1434" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; white-space: nowrap;"> ) </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Net deferred tax assets </td> <td id="new_id-1435" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1436" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-1437" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-1438" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> <td id="new_id-1439" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td id="new_id-1440" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td id="new_id-1441" style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td id="new_id-1442" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; white-space: nowrap;"> </td> </tr> </table></div>

238591

905723

238591

905723

<div style="font-family: Times New Roman; font-size: 10pt; "> NOTE 8 – SUBSEQUENT EVENTS On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s annual report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology (with estimated value of USD $29.8 million) to the JV Company as its capital contribution, to account for 40% equity ownership. 1) Shares issued for merger & acquisition Investment in Brilliant Healthcare Limited On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s annual report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology (with estimated value of USD $29.8 million) to the JV Company as its capital contribution, to account for 40% equity ownership.  Investment in Imedipus Inc. On January 30, 2020, the Company and Imediplus Inc. (“Imediplus”), a leading medical institution in Taiwan, entered into a Cooperation Agreement, in which the Company agreed to acquire 48% of the equity of Imediplus, as consideration, the Company shall pay $1,000,000 and issue 662,000,000 common shares to Imediplus. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. As of June 30, 2021, the Company has not completed its financial and legal due diligence and has not consummated the acquisition of Imediplus. On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus. Investment in Purecell Group On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence.  On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell") in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at market price of $0.14 per share. On May 11, 2021, Aussie Produce PTY LTD ("AP") signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP.  2) Shares issued for stock compensation On January 22, 2021, the Company issued an aggregate of 48,220,124 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.06 per share.  On March 10, 2021, the Company issued an aggregate of 79,362,534 shares of common stock to 54 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.13 per share. On April 7, 2021, the Company issued an aggregate of 6,621,905 shares of common stock to 12 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.13 per share. On May 5, 2021, the Company issued an aggregate of 1,300,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share. On May 18, 2021, the Company issued an aggregate of 7,140,000 shares of common stock to 5 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share.  On May 18, 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company of relevant theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology; Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. As consideration, the Company agreed to grant 8 million shares of AAGH common stock to Dr. Tsai along with certain monthly compensations and sales bonus.  On May 26, 2021, the Company issued an aggregate of 2,450,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.15 per share.  On June 18, 2021, the Company issued an aggregate of 11,300,000 shares of common stock to 22 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.16 per share.  3) Shares issued for loan as collateral On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.04 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on April 27, 2021.  On June 18, 2021, the Company issued an aggregate of 3,050,000 shares to 6 unrelated parties as collateral for loans of $290,000. The loans have an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 3, 2021.  On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date , the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 4, 2021.  </div>

4200000

0.60

29800000

0.40

0.48

1000000

662000000

70000000

2500000

0.05

0.51

510000000

0.51

50000000

0.14

2340000

0.06

35000000

68372

71163

31212000

48220124

0.06

79362534

0.13

6621905

0.13

1300000

0.14

7140000

0.14

8000000

2450000

0.15

11300000

0.16

10000000

200000

0.20

P5Y

If the Company's stock price remains above $0.04 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven.

3050000

290000

0.20

P5Y

If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven.

500000

50000

0.20

P5Y

If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date , the stock will become tradable and the remaining principle and interest of loan will be forgiven.

EX-101.SCH 5 aagh-20200630.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statement of Shareholders' Deficit link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - NATURE OF BUSINESS link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - SHAREHOLDERS' DEFICIT link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - JOINT VENTURE link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - JOINT VENTURE (Tables) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - NATURE OF BUSINESS (Details) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - SHAREHOLDERS' DEFICIT (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - JOINT VENTURE (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - JOINT VENTURE (Details) - Equity Method Investments link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - JOINT VENTURE (Details) - Equity Method Investments (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - INCOME TAXES (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 aagh-20200630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 aagh-20200630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 aagh-20200630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Statement of Financial Position [Abstract] Cash Other receivable TOTAL CURRENT ASSETS TOTAL ASSETS Total assets Accounts payable and accrued expense Due to related party Due to Related Parties, Current TOTAL CURRENT LIABILITIES TOTAL SHAREHOLDERS' DEFICIT Balance Balance Stockholders' Equity Attributable to Parent TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT Net assets Income Statement [Abstract] Sales Cost of goods sold Gross profit Gross profit Professional fee Other Loss from operations Loss on investment Loss on investment 49% share Loss before income tax Income tax provision NET LOSS Net loss Net Income (Loss) Attributable to Parent Statement of Stockholders' Equity [Abstract] Balance (in Shares) Balance (in Shares) Common stock, shares outstanding Common Stock, Shares, Outstanding Equity Components [Axis] Statement of Cash Flows [Abstract] Net loss Other receivable Accounts payable and accrued expense Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Advances from related party Proceeds from Related Party Debt Net cash provided by financing activities Net increase (decrease) in cash Cash beginning of period Cash end of period Accounting Policies [Abstract] Related Party Transactions [Abstract] Stockholders' Equity Note [Abstract] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments [Abstract] Related Party [Axis] Income Tax Disclosure [Abstract] Schedule of Effective Income Tax Rate Reconciliation [Abstract] Schedule of Deferred Tax Assets and Liabilities [Abstract] Net deferred tax assets Subsequent Events [Abstract] Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Current Reporting Status Entity Emerging Growth Company Entity Filer Category Entity Interactive Data Current Entity Public Float Entity Registrant Name Entity Shell Company Entity Small Business Entity Voluntary Filers Entity Well-known Seasoned Issuer ASSETS CURRENT ASSETS Inventory LIABILITIES AND SHAREHOLDERS' DEFICIT CURRENT LIABILITIES Income tax payable SHAREHOLDERS' DEFICIT Redeemable, convertible preferred stock, 10,000,000 shares authorized; Series A voting preferred stock, zero shares issued and outstanding Series A voting preferred stock, shares issued Series A voting preferred stock, shares outstanding Redeemable, convertible preferred stock, shares authorized Common stock, no par value, unlimited shares authorized; 20,236,021,836 and 20,236,021,836 shares issued and outstanding Common stock, shares issued Common Stock, Shares, Issued Additional paid-in capital Accumulated deficit Selling, general and administrative expenses Other income (expenses) Loss on disposal of investment Loss on disposal of investment Gain (Loss) on Disposition of Assets BASIC AND DILUTED LOSS PER SHARE (in Dollars per share) WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED (in Shares) Imputed Interest Imputed interest Cash Flows from Operating Activities Adjustments to reconcile net loss to net cash used in operating activities: Changes in operating Assets and Liabilities: Income tax payable Cash Flows from Financing Activities Interest paid Taxes paid Interest expense Inventory Repayment to related party Repayments of Related Party Debt Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Significant Accounting Policies [Text Block] Related Party Transactions Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Equity Method Investments and Joint Ventures Disclosure [Text Block] Equity Method Investments [Table Text Block] 49% ownership Ownership Equity Method Investment, Ownership Percentage Ending balance of investment account before written off Difference Foreign Currency Transaction Gain (Loss), Realized Income Tax Disclosure [Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Income tax benefit at federal statutory rate State tax, net of fed effect Change in valuation allowance Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Net operating loss carryforwards Subsequent Events [Text Block] Less: valuation allowance Corporate Joint Venture [Member] Investment, Name [Axis] Legal Entity [Axis] Subsequent Event Type [Axis] Ownership [Axis] Business Acquisition [Axis] Debt Instrument [Axis] Stock Issued During Period, Shares, Acquisitions (in Shares) Stock Issued During Period, Shares, Acquisitions Proceeds from Sales of Business, Affiliate and Productive Assets Payments to Acquire Interest in Joint Venture Payments to Acquire Interest in Joint Venture (in Dollars) Operating Loss Carryforwards Noncontrolling Interest in Joint Ventures (in Dollars) Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Payments to Acquire Businesses, Gross (in Dollars) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Number of shareholders Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture Shares Issued, Price Per Share (in Dollars per share) Proceeds from Issuance or Sale of Equity (in Dollars) Stock Issued During Period, Shares, New Issues Sale of Stock, Number of Shares Issued in Transaction Stock Issued During Period, Shares, Issued for Services Number of Unrelated Parties Stock Issued During Period, Shares, Other Debt Instrument, Face Amount (in Dollars) Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Term Long-term Debt, Maturities, Repayment Terms Basis of Accounting, Policy [Policy Text Block] Consolidation, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Revenue [Policy Text Block] Fair Value Measurement, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Guangzhou Bona Niotechnology Co., Ltd [Member] Subsequent Event [Member] Brilliant Healthcare Limited [Member] Imediplus Inc. [Member] Purecell Group [Member] Aussie Produce PTY LTD [Member] Dr. Tsai [Member] Loan #1 [Member] Loan #2 [Member] Loan #3 [Member] Equity Component [Domain] Related Party [Domain] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Entity [Domain] Investment, Name [Domain] JOINT VENTURE (Details) [Table] JOINT VENTURE (Details) [Line Items] Debt Instrument, Name [Domain] Ownership [Domain] Business Acquisition, Acquiree [Domain] Subsequent Event Type [Domain] SUBSEQUENT EVENTS (Details) [Table] SUBSEQUENT EVENTS (Details) [Line Items] Imputed interest. Number of shareholders. Number of unrelated parties. Name of legal entity. EX-101.PRE 9 aagh-20200630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Jun. 30, 2020	Jul. 12, 2021	Dec. 31, 2018
Document Information Line Items
Entity Registrant Name	America Great Health
Document Type	10-K
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		21,070,866,399
Entity Public Float			$ 0
Amendment Flag	false
Entity Central Index Key	0001098009
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	No

XML 11 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Jun. 30, 2019
CURRENT ASSETS
Cash	$ 166	$ 102
Inventory	1,141	0
Other receivable	2,587	0
TOTAL CURRENT ASSETS	3,894	102
TOTAL ASSETS	3,894	102
CURRENT LIABILITIES
Accounts payable and accrued expense	49,273	38,900
Income tax payable	1,600	800
Due to related party	168,028	128,404
TOTAL CURRENT LIABILITIES	218,901	168,104
SHAREHOLDERS' DEFICIT
Redeemable, convertible preferred stock, 10,000,000 shares authorized; Series A voting preferred stock, zero shares issued and outstanding	0	0
Common stock, no par value, unlimited shares authorized; 20,236,021,836 and 20,236,021,836 shares issued and outstanding	0	0
Additional paid-in capital	3,071,635	3,066,724
Accumulated deficit	(3,286,642)	(3,234,726)
TOTAL SHAREHOLDERS' DEFICIT	(215,007)	(168,002)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 3,894	$ 102

XML 12 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parentheticals) - shares	Jun. 30, 2020	Jun. 30, 2019
Statement of Financial Position [Abstract]
Series A voting preferred stock, shares issued	0	0
Series A voting preferred stock, shares outstanding	0	0
Redeemable, convertible preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	20,236,021,836	20,236,021,836
Common stock, shares outstanding	20,236,021,836	20,236,021,836

XML 13 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Sales	$ 5,474	$ 0
Cost of goods sold	3,369	0
Gross profit	2,105	0
Selling, general and administrative expenses
Professional fee	34,255	33,507
Other	14,001	13,264
	48,256	46,771
Loss from operations	(46,151)	(46,771)
Other income (expenses)
Interest expense	(4,965)	(4,494)
Loss on investment	0	(966)
Loss on disposal of investment	0	(12,012)
	(4,965)	(17,472)
Loss before income tax	(51,116)	(64,243)
Income tax provision	800	800
NET LOSS	$ (51,916)	$ (65,043)
BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)	$ 0.00	$ 0.00
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED (in Shares)	20,236,021,836	20,236,021,836

XML 14 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Shareholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Jun. 30, 2018		$ 3,062,230	$ (3,169,683)	$ (107,453)
Balance (in Shares) at Jun. 30, 2018	20,236,021,836
Imputed Interest		4,494		4,494
Net loss			(65,043)	(65,043)
Balance at Jun. 30, 2019		3,066,724	(3,234,726)	$ (168,002)
Balance (in Shares) at Jun. 30, 2019	20,236,021,836			20,236,021,836
Imputed Interest		4,911		$ 4,911
Net loss			(51,916)	(51,916)
Balance at Jun. 30, 2020		$ 3,071,635	$ (3,286,642)	$ (215,007)
Balance (in Shares) at Jun. 30, 2020	20,236,021,836			20,236,021,836

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows from Operating Activities
Net loss	$ (51,916)	$ (65,043)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on investment	0	966
Loss on disposal of investment	0	12,012
Imputed interest	4,911	4,494
Changes in operating Assets and Liabilities:
Inventory	(1,141)	0
Other receivable	(2,587)	100
Accounts payable and accrued expense	10,374	18,879
Income tax payable	800	800
Net cash used in operating activities	(39,559)	(27,792)
Cash Flows from Financing Activities
Advances from related party	121,840	29,379
Repayment to related party	(82,217)	(1,500)
Net cash provided by financing activities	39,623	27,879
Net increase (decrease) in cash	64	87
Cash beginning of period	102	15
Cash end of period	166	102
Interest paid	0	0
Taxes paid	$ 0	$ 0

XML 16 R7.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS	12 Months Ended
NATURE OF BUSINESS	Jun. 30, 2020
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 – NATURE OF BUSINESS History and Organization America Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations. On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health. On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California. On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China. Going Concern The accompanying consolidated financial statements (“CFS”) were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2020, the Company recorded a net loss of $51,916, used cash to fund operating activities of $39,559, and at June 30, 2020, had a shareholders’ deficit of $215,007. These factors create substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations. Our cash needs for the 12 months ended June 30, 2020 were primarily met by loans and advances from current majority shareholder. As of June 30, 2020, we had a cash balance of $166. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder.

XML 17 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Basis of Consolidation

Estimates

Revenues

●

executed contract(s) with customers that the Company believes is legally enforceable;

●

identification of performance obligation in the respective contract;

●

determination of the transaction price for each performance obligation in the respective contract;

●

allocation of the transaction price to each performance obligation; and

●

recognition of revenue only when the Company satisfies each performance obligation.

Inventories

Fair Value Measurements

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s assumptions.

The Company is required to use observable market data if available without undue cost and effort.

The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.

Loss per Share

Income Taxes

Recent Accounting Pronouncements

XML 18 R9.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS	12 Months Ended
RELATED PARTY TRANSACTIONS	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 3 – RELATED PARTY TRANSACTIONS During the year ended June 30, 2020, the Company's current majority shareholder advanced $121,840 to the Company as working capital and the Company repaid $82,217 to the shareholder. As of June 30, 2020 and 2019, the Company owed its current majority shareholder of $168,028 and $128,404 respectively. The advances are non-interest bearing and are due on demand. Currently the Company is using a premise for free, the premises is leased by a company owned by its current majority shareholder.

XML 19 R10.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' DEFICIT	12 Months Ended
SHAREHOLDERS' DEFICIT	Jun. 30, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 4 – SHAREHOLDERS’ DEFICIT At June 30, 2020 and 2019, the Company had 20,236,021,836 shares issued and outstanding.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 20 R11.htm IDEA: XBRL DOCUMENT

JOINT VENTURE

12 Months Ended

Jun. 30, 2020

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments and Joint Ventures Disclosure [Text Block]

NOTE 5 – JOINT VENTURE

The following table summarizes the income statement of Pomeikang.

	From date of equity investment to 12/31/2018

Sales	$	20,740
Gross profit		13,739
Net loss		(2,803	)
49% share		(1,373	)

The following table provides the summary of balance sheet information for Pomeikang.

	As of December 31, 2018

Total assets	$	20,565
Net assets		20,565
49% ownership		10,077
Ending balance of investment account before written off		12,012
Difference		(1,932	)

The difference of $1,932 was mainly due to the effect of exchange rate.

XML 21 R12.htm IDEA: XBRL DOCUMENT

INCOME TAXES

12 Months Ended

Jun. 30, 2020

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

NOTE 6 – INCOME TAXES

	Year Ended June 30,
	2020			2019

Income tax benefit at federal statutory rate		21	%		21	%
State tax, net of fed effect		7	%		7	%
Change in valuation allowance		-28	%		-28	%
		-	%		-	%

The components of deferred taxes consist of the following at June 30, 2020 and 2019:

	June 30, 2020			June 30, 2019

Net operating loss carryforwards	$	238,591		$	905,723
Less: valuation allowance		(238,591	)		(905,723	)
Net deferred tax assets	$	-		$	-

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 22 R13.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 8 – SUBSEQUENT EVENTS On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s annual report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology (with estimated value of USD $29.8 million) to the JV Company as its capital contribution, to account for 40% equity ownership. 1) Shares issued for merger & acquisition Investment in Brilliant Healthcare Limited On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s annual report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology (with estimated value of USD $29.8 million) to the JV Company as its capital contribution, to account for 40% equity ownership. Investment in Imedipus Inc. On January 30, 2020, the Company and Imediplus Inc. (“Imediplus”), a leading medical institution in Taiwan, entered into a Cooperation Agreement, in which the Company agreed to acquire 48% of the equity of Imediplus, as consideration, the Company shall pay $1,000,000 and issue 662,000,000 common shares to Imediplus. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. As of June 30, 2021, the Company has not completed its financial and legal due diligence and has not consummated the acquisition of Imediplus. On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus. Investment in Purecell Group On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell") in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at market price of $0.14 per share. On May 11, 2021, Aussie Produce PTY LTD ("AP") signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP. 2) Shares issued for stock compensation On January 22, 2021, the Company issued an aggregate of 48,220,124 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.06 per share. On March 10, 2021, the Company issued an aggregate of 79,362,534 shares of common stock to 54 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.13 per share. On April 7, 2021, the Company issued an aggregate of 6,621,905 shares of common stock to 12 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.13 per share. On May 5, 2021, the Company issued an aggregate of 1,300,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share. On May 18, 2021, the Company issued an aggregate of 7,140,000 shares of common stock to 5 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share. On May 18, 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company of relevant theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology; Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. As consideration, the Company agreed to grant 8 million shares of AAGH common stock to Dr. Tsai along with certain monthly compensations and sales bonus. On May 26, 2021, the Company issued an aggregate of 2,450,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.15 per share. On June 18, 2021, the Company issued an aggregate of 11,300,000 shares of common stock to 22 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.16 per share. 3) Shares issued for loan as collateral On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.04 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on April 27, 2021. On June 18, 2021, the Company issued an aggregate of 3,050,000 shares to 6 unrelated parties as collateral for loans of $290,000. The loans have an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 3, 2021. On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date , the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 4, 2021.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

12 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Consolidation, Policy [Policy Text Block]

Basis of Consolidation

Use of Estimates, Policy [Policy Text Block]

Estimates

Revenue [Policy Text Block]

Revenues

●

executed contract(s) with customers that the Company believes is legally enforceable;

●

identification of performance obligation in the respective contract;

●

determination of the transaction price for each performance obligation in the respective contract;

●

allocation of the transaction price to each performance obligation; and

●

recognition of revenue only when the Company satisfies each performance obligation.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s assumptions.

The Company is required to use observable market data if available without undue cost and effort.

The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.

Earnings Per Share, Policy [Policy Text Block]

Loss per Share

Income Tax, Policy [Policy Text Block]

Income Taxes

Inventory, Policy [Policy Text Block]

Inventories

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

XML 24 R15.htm IDEA: XBRL DOCUMENT

JOINT VENTURE (Tables)

12 Months Ended

Jun. 30, 2020

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments [Table Text Block]

	From date of equity investment to 12/31/2018

Sales	$	20,740
Gross profit		13,739
Net loss		(2,803	)
49% share		(1,373	)

	As of December 31, 2018

Total assets	$	20,565
Net assets		20,565
49% ownership		10,077
Ending balance of investment account before written off		12,012
Difference		(1,932	)

XML 25 R16.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

12 Months Ended

Jun. 30, 2020

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Year Ended June 30,
	2020			2019

Income tax benefit at federal statutory rate		21	%		21	%
State tax, net of fed effect		7	%		7	%
Change in valuation allowance		-28	%		-28	%
		-	%		-	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

The components of deferred taxes consist of the following at June 30, 2020 and 2019:

	June 30, 2020			June 30, 2019

Net operating loss carryforwards	$	238,591		$	905,723
Less: valuation allowance		(238,591	)		(905,723	)
Net deferred tax assets	$	-		$	-

XML 26 R17.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS (Details) - USD ($)		12 Months Ended
NATURE OF BUSINESS (Details) - USD ($)	Jan. 19, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Accounting Policies [Abstract]
Stock Issued During Period, Shares, Acquisitions (in Shares)	16,155,746,000
Proceeds from Sales of Business, Affiliate and Productive Assets	$ 100
Net Income (Loss) Attributable to Parent		$ (51,916)	$ (65,043)
Net Cash Provided by (Used in) Operating Activities		(39,559)	(27,792)
Stockholders' Equity Attributable to Parent		(215,007)	(168,002)	$ (107,453)
Cash		$ 166	$ 102

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

XML 27 R18.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details) - USD ($)	12 Months Ended
RELATED PARTY TRANSACTIONS (Details) - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Related Party Transactions [Abstract]
Proceeds from Related Party Debt	$ 121,840	$ 29,379
Repayments of Related Party Debt	82,217	1,500
Due to Related Parties, Current	$ 168,028	$ 128,404

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

+ Details

XML 28 R19.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' DEFICIT (Details) - shares	Jun. 30, 2020	Jun. 30, 2019
Stockholders' Equity Note [Abstract]
Common Stock, Shares, Issued	20,236,021,836	20,236,021,836
Common Stock, Shares, Outstanding	20,236,021,836	20,236,021,836

XML 29 R20.htm IDEA: XBRL DOCUMENT

JOINT VENTURE (Details) ¥ in Thousands		12 Months Ended				15 Months Ended
JOINT VENTURE (Details) ¥ in Thousands	Apr. 01, 2019 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2018 CNY (¥)	Dec. 31, 2018 USD ($)
JOINT VENTURE (Details) [Line Items]
Equity Method Investment, Ownership Percentage				49.00%	49.00%
Payments to Acquire Interest in Joint Venture \| ¥					¥ 2,450
Foreign Currency Transaction Gain (Loss), Realized				$ 1,932
Gain (Loss) on Disposition of Assets		$ 0	$ (12,012)			$ (12,012)
Guangzhou Bona Niotechnology Co., Ltd [Member]
JOINT VENTURE (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49.00%
Payments to Acquire Interest in Joint Venture	$ 1
Guangzhou Bona Niotechnology Co., Ltd [Member]
JOINT VENTURE (Details) [Line Items]
Equity Method Investment, Ownership Percentage				51.00%	51.00%

XML 30 R21.htm IDEA: XBRL DOCUMENT

JOINT VENTURE (Details) - Equity Method Investments - Corporate Joint Venture [Member]	10 Months Ended
	Dec. 31, 2018 USD ($)
Schedule of Equity Method Investments [Line Items]
Sales	$ 20,740
Gross profit	13,739
Net loss	(2,803)
49% share	(1,373)
Total assets	20,565
Net assets	20,565
49% ownership	10,077
Ending balance of investment account before written off	12,012
Difference	$ (1,932)

XML 31 R22.htm IDEA: XBRL DOCUMENT

JOINT VENTURE (Details) - Equity Method Investments (Parentheticals)	Dec. 31, 2018
Corporate Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Ownership	49.00%

XML 32 R23.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) $ in Millions	Jun. 30, 2020 USD ($)
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 852,111

XML 33 R24.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Income tax benefit at federal statutory rate	21.00%	21.00%
State tax, net of fed effect	7.00%	7.00%
Change in valuation allowance	(28.00%)	(28.00%)
	0.00%	0.00%

XML 34 R25.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Schedule of Deferred Tax Assets and Liabilities [Abstract]
Net operating loss carryforwards	$ 238,591	$ 905,723
Less: valuation allowance	(238,591)	(905,723)
Net deferred tax assets	$ 0	$ 0

XML 35 R26.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details) $ / shares in Units, ¥ in Thousands														12 Months Ended
	Jun. 18, 2021 USD ($) $ / shares shares	May 26, 2021 $ / shares shares	May 18, 2021 $ / shares shares	May 11, 2021 USD ($) shares	May 05, 2021 USD ($) $ / shares shares	Apr. 07, 2021 $ / shares shares	Apr. 06, 2021 $ / shares shares	Mar. 10, 2021 $ / shares shares	Jan. 22, 2021 $ / shares shares	Dec. 07, 2020 USD ($)	Jun. 30, 2020 shares	Jan. 30, 2020 USD ($) shares	Jan. 19, 2017 shares	Jun. 30, 2018 CNY (¥)	Dec. 31, 2018
SUBSEQUENT EVENTS (Details) [Line Items]
Payments to Acquire Interest in Joint Venture (in Dollars) \| ¥														¥ 2,450
Equity Method Investment, Ownership Percentage														49.00%
Stock Issued During Period, Shares, Acquisitions													16,155,746,000
Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) \| $ / shares	$ 0.16	$ 0.15	$ 0.14		$ 0.14	$ 0.13		$ 0.13	$ 0.06
Stock Issued During Period, Shares, Issued for Services	11,300,000	2,450,000	7,140,000		1,300,000	6,621,905		79,362,534	48,220,124
Number of Unrelated Parties	22	6	5		6	12		54	28
Imediplus Inc. [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage												48.00%
Payments to Acquire Businesses, Gross (in Dollars) \| $												$ 1,000,000
Stock Issued During Period, Shares, Acquisitions												662,000,000
Imediplus Inc. [Member] \| Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage							5.00%
Stock Issued During Period, Shares, Acquisitions							70,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares							2,500,000
Purecell Group [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage											51.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares											510,000,000
Purecell Group [Member] \| Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage							51.00%
Stock Issued During Period, Shares, Acquisitions				31,212,000
Number of shareholders							2
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture							50,000,000
Shares Issued, Price Per Share (in Dollars per share) \| $ / shares							$ 0.14
Sale of Stock, Number of Shares Issued in Transaction				71,163
Corporate Joint Venture [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage															49.00%
Corporate Joint Venture [Member] \| Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Payments to Acquire Interest in Joint Venture (in Dollars) \| $										$ 4,200,000
Equity Method Investment, Ownership Percentage										60.00%
Noncontrolling Interest in Joint Ventures (in Dollars) \| $										$ 29,800,000
Dr. Tsai [Member] \| Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services			8,000,000
Aussie Produce PTY LTD [Member] \| Purecell Group [Member] \| Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage				6.00%
Proceeds from Issuance or Sale of Equity (in Dollars) \| $				$ 2,340,000
Stock Issued During Period, Shares, New Issues				35,000,000
Sale of Stock, Number of Shares Issued in Transaction				68,372
Brilliant Healthcare Limited [Member] \| Corporate Joint Venture [Member] \| Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners										40.00%
Loan #1 [Member] \| Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Other					10,000,000
Debt Instrument, Face Amount (in Dollars) \| $					$ 200,000
Debt Instrument, Interest Rate, Stated Percentage					20.00%
Debt Instrument, Term					5 years
Long-term Debt, Maturities, Repayment Terms					If the Company's stock price remains above $0.04 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven.
Loan #2 [Member] \| Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Number of Unrelated Parties	6
Stock Issued During Period, Shares, Other	3,050,000
Debt Instrument, Face Amount (in Dollars) \| $	$ 290,000
Debt Instrument, Interest Rate, Stated Percentage	20.00%
Debt Instrument, Term	5 years
Long-term Debt, Maturities, Repayment Terms	If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven.
Loan #3 [Member] \| Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Other	500,000
Debt Instrument, Face Amount (in Dollars) \| $	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	20.00%
Debt Instrument, Term	5 years
Long-term Debt, Maturities, Repayment Terms	If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date , the stock will become tradable and the remaining principle and interest of loan will be forgiven.

EXCEL 36 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 38 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 63 199 1 false 15 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://cwnm.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://cwnm.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://cwnm.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://cwnm.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statement of Shareholders' Deficit Sheet http://cwnm.com/role/ShareholdersEquityType2or3 Consolidated Statement of Shareholders' Deficit Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://cwnm.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - NATURE OF BUSINESS Sheet http://cwnm.com/role/NATUREOFBUSINESS NATURE OF BUSINESS Notes 7 false false R8.htm 007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://cwnm.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 008 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://cwnm.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 9 false false R10.htm 009 - Disclosure - SHAREHOLDERS' DEFICIT Sheet http://cwnm.com/role/SHAREHOLDERSDEFICIT SHAREHOLDERS' DEFICIT Notes 10 false false R11.htm 010 - Disclosure - JOINT VENTURE Sheet http://cwnm.com/role/JOINTVENTURE JOINT VENTURE Notes 11 false false R12.htm 011 - Disclosure - INCOME TAXES Sheet http://cwnm.com/role/INCOMETAXES INCOME TAXES Notes 12 false false R13.htm 012 - Disclosure - SUBSEQUENT EVENTS Sheet http://cwnm.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 13 false false R14.htm 013 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://cwnm.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies 14 false false R15.htm 014 - Disclosure - JOINT VENTURE (Tables) Sheet http://cwnm.com/role/JOINTVENTURETables JOINT VENTURE (Tables) Tables http://cwnm.com/role/JOINTVENTURE 15 false false R16.htm 015 - Disclosure - INCOME TAXES (Tables) Sheet http://cwnm.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://cwnm.com/role/INCOMETAXES 16 false false R17.htm 016 - Disclosure - NATURE OF BUSINESS (Details) Sheet http://cwnm.com/role/NATUREOFBUSINESSDetails NATURE OF BUSINESS (Details) Details http://cwnm.com/role/NATUREOFBUSINESS 17 false false R18.htm 018 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://cwnm.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://cwnm.com/role/RELATEDPARTYTRANSACTIONS 18 false false R19.htm 019 - Disclosure - SHAREHOLDERS' DEFICIT (Details) Sheet http://cwnm.com/role/SHAREHOLDERSDEFICITDetails SHAREHOLDERS' DEFICIT (Details) Details http://cwnm.com/role/SHAREHOLDERSDEFICIT 19 false false R20.htm 020 - Disclosure - JOINT VENTURE (Details) Sheet http://cwnm.com/role/JOINTVENTUREDetails JOINT VENTURE (Details) Details http://cwnm.com/role/JOINTVENTURETables 20 false false R21.htm 021 - Disclosure - JOINT VENTURE (Details) - Equity Method Investments Sheet http://cwnm.com/role/EquityMethodInvestmentsTable JOINT VENTURE (Details) - Equity Method Investments Details http://cwnm.com/role/JOINTVENTURETables 21 false false R22.htm 022 - Disclosure - JOINT VENTURE (Details) - Equity Method Investments (Parentheticals) Sheet http://cwnm.com/role/EquityMethodInvestmentsTable_Parentheticals JOINT VENTURE (Details) - Equity Method Investments (Parentheticals) Details http://cwnm.com/role/JOINTVENTURETables 22 false false R23.htm 023 - Disclosure - INCOME TAXES (Details) Sheet http://cwnm.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://cwnm.com/role/INCOMETAXESTables 23 false false R24.htm 024 - Disclosure - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation Sheet http://cwnm.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation Details http://cwnm.com/role/INCOMETAXESTables 24 false false R25.htm 025 - Disclosure - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities Sheet http://cwnm.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities Details http://cwnm.com/role/INCOMETAXESTables 25 false false R26.htm 026 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://cwnm.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://cwnm.com/role/SUBSEQUENTEVENTS 26 false false All Reports Book All Reports aagh-20200630.xml aagh-20200630.xsd aagh-20200630_cal.xml aagh-20200630_def.xml aagh-20200630_lab.xml aagh-20200630_pre.xml http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true true ZIP 41 0001185185-21-000951-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001185185-21-000951-xbrl.zip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end